Yellow fever live attenuated vaccine

A very successful live attenuated vaccine but still we have problems controlling the disease

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Yellow fever (YF) is regarded as the original hemorrhagic fever and has been a major public health problem for at least 250. years. A very effective live attenuated vaccine, strain 17D, was developed in the 1930s and this has proved critical in the control of the disease. There is little doubt that without the vaccine, YF virus would be considered a biosafety level 4 pathogen. Significantly, YF is currently the only disease where an international vaccination certificate is required under the International Health Regulations. Despite having a very successful vaccine, there are occasional issues of supply and demand, such as that which occurred in Angola and Democratic Republic of Congo in 2016 when there was insufficient vaccine available. For the first time fractional dosing of the vaccine was approved on an emergency basis. Thus, continued vigilance and improvements in supply and demand are needed in the future.

Original languageEnglish (US)
JournalVaccine
DOIs
StateAccepted/In press - 2017

Fingerprint

Yellow fever virus
Yellow Fever
Attenuated Vaccines
live vaccines
Vaccines
vaccines
supply balance
Angola
Democratic Republic of the Congo
biosafety
fever
public health
disease control
Vaccination
Emergencies
Fever
Public Health
vaccination
pathogens
Health

Keywords

  • Flavivirus
  • Fractional dosing
  • International health regulations
  • Vaccine
  • Yellow fever

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

@article{73a39b3b74f340bba9933f0a8e690825,
title = "Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease",
abstract = "Yellow fever (YF) is regarded as the original hemorrhagic fever and has been a major public health problem for at least 250. years. A very effective live attenuated vaccine, strain 17D, was developed in the 1930s and this has proved critical in the control of the disease. There is little doubt that without the vaccine, YF virus would be considered a biosafety level 4 pathogen. Significantly, YF is currently the only disease where an international vaccination certificate is required under the International Health Regulations. Despite having a very successful vaccine, there are occasional issues of supply and demand, such as that which occurred in Angola and Democratic Republic of Congo in 2016 when there was insufficient vaccine available. For the first time fractional dosing of the vaccine was approved on an emergency basis. Thus, continued vigilance and improvements in supply and demand are needed in the future.",
keywords = "Flavivirus, Fractional dosing, International health regulations, Vaccine, Yellow fever",
author = "Alan Barrett",
year = "2017",
doi = "10.1016/j.vaccine.2017.03.032",
language = "English (US)",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Yellow fever live attenuated vaccine

T2 - A very successful live attenuated vaccine but still we have problems controlling the disease

AU - Barrett, Alan

PY - 2017

Y1 - 2017

N2 - Yellow fever (YF) is regarded as the original hemorrhagic fever and has been a major public health problem for at least 250. years. A very effective live attenuated vaccine, strain 17D, was developed in the 1930s and this has proved critical in the control of the disease. There is little doubt that without the vaccine, YF virus would be considered a biosafety level 4 pathogen. Significantly, YF is currently the only disease where an international vaccination certificate is required under the International Health Regulations. Despite having a very successful vaccine, there are occasional issues of supply and demand, such as that which occurred in Angola and Democratic Republic of Congo in 2016 when there was insufficient vaccine available. For the first time fractional dosing of the vaccine was approved on an emergency basis. Thus, continued vigilance and improvements in supply and demand are needed in the future.

AB - Yellow fever (YF) is regarded as the original hemorrhagic fever and has been a major public health problem for at least 250. years. A very effective live attenuated vaccine, strain 17D, was developed in the 1930s and this has proved critical in the control of the disease. There is little doubt that without the vaccine, YF virus would be considered a biosafety level 4 pathogen. Significantly, YF is currently the only disease where an international vaccination certificate is required under the International Health Regulations. Despite having a very successful vaccine, there are occasional issues of supply and demand, such as that which occurred in Angola and Democratic Republic of Congo in 2016 when there was insufficient vaccine available. For the first time fractional dosing of the vaccine was approved on an emergency basis. Thus, continued vigilance and improvements in supply and demand are needed in the future.

KW - Flavivirus

KW - Fractional dosing

KW - International health regulations

KW - Vaccine

KW - Yellow fever

UR - http://www.scopus.com/inward/record.url?scp=85016490833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016490833&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2017.03.032

DO - 10.1016/j.vaccine.2017.03.032

M3 - Article

JO - Vaccine

JF - Vaccine

SN - 0264-410X

ER -